Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16895293 | 0.84 | PPARG (0.33) | FFAR1HRH3 | |
| SCHEMBL4951364 | 0.83 | SLC7A5 (0.39) | FFAR1HRH3CYP2D6ALKHAO1 | |
| SCHEMBL5888774 | 0.82 | ASIC3 (0.39) | FFAR1HRH3CYP2D6ALKASIC3 | |
| SCHEMBL7396970 | 0.81 | CYP1A2 (0.39) | HRH3HTR2CHTR2B | |
| SCHEMBL1246811 | 0.75 | PRKCI (0.33) | ALKPRKCI | |
| SCHEMBL21068770 | 0.74 | DUT (0.37) | PRKCI | |
| SCHEMBL20496654 | 0.74 | DUT (0.39) | HRH3 | |
| SCHEMBL17367310 | 0.73 | SHMT1 (0.33) | — | |
| SCHEMBL501378 | 0.73 | MRGPRX4 (0.41) | PRKCI | |
| SCHEMBL16895309 | 0.73 | KDR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | FFAR1 934/4885HRH3 98/4885CYP2D6 648/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | FFAR1 934/4885HRH3 98/4885CYP2D6 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.